Kristi Baker

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3828952/publications.pdf

Version: 2024-02-01

109321 138484 3,965 61 35 58 citations h-index g-index papers 63 63 63 6549 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Bacteriophage Transcytosis Provides a Mechanism To Cross Epithelial Cell Layers. MBio, 2017, 8, .	4.1	273
2	Advanced colorectal polyps with the molecular and morphological features of serrated polyps and adenomas: concept of a †fusion†pathway to colorectal cancer. Histopathology, 2006, 49, 121-131.	2.9	230
3	Neonatal Fc Receptor: From Immunity to Therapeutics. Journal of Clinical Immunology, 2010, 30, 777-789.	3.8	208
4	Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics. Critical Reviews in Biotechnology, 2015, 35, 235-254.	9.0	201
5	FcRn: The Architect Behind the Immune and Nonimmune Functions of IgG and Albumin. Journal of Immunology, 2015, 194, 4595-4603.	0.8	199
6	Neonatal Fc receptor for IgG (FcRn) regulates cross-presentation of IgG immune complexes by CD8 ^{â^'} CD11b ⁺ dendritic cells. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 9927-9932.	7.1	187
7	Protective mucosal immunity mediated by epithelial CD1d and IL-10. Nature, 2014, 509, 497-502.	27.8	172
8	Extensive DNA methylation in normal colorectal mucosa in hyperplastic polyposis. Gut, 2006, 55, 1467-1474.	12.1	131
9	The Immunologic Functions of the Neonatal Fc Receptor for IgG. Journal of Clinical Immunology, 2013, 33, 9-17.	3.8	120
10	Loss of Raf-1 Kinase Inhibitor Protein Expression Is Associated With Tumor Progression and Metastasis in Colorectal Cancer. American Journal of Clinical Pathology, 2007, 127, 820-827.	0.7	119
11	Prognostic significance of the wnt signalling pathway molecules APC, ?-catenin and E-cadherin in colorectal cancer?a tissue microarray-based analysis. Histopathology, 2007, 50, 453-464.	2.9	118
12	Immune and non-immune functions of the (not so) neonatal Fc receptor, FcRn. Seminars in Immunopathology, 2009, 31, 223-236.	6.1	115
13	Neonatal Fc Receptor Expression in Dendritic Cells Mediates Protective Immunity against Colorectal Cancer. Immunity, 2013, 39, 1095-1107.	14.3	112
14	Prognostic significance of CD8+ T lymphocytes in breast cancer depends upon both oestrogen receptor status and histological grade. Histopathology, 2011, 58, no-no.	2.9	104
15	The Role of FcRn in Antigen Presentation. Frontiers in Immunology, 2014, 5, 408.	4.8	88
16	A Critical Review on the Effect of Docosahexaenoic Acid (DHA) on Cancer Cell Cycle Progression. International Journal of Molecular Sciences, 2017, 18, 1784.	4.1	86
17	Hepatic FcRn regulates albumin homeostasis and susceptibility to liver injury. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E2862-E2871.	7.1	84
18	An FcRn-Dependent Role for Anti-flagellin Immunoglobulin G in Pathogenesis of Colitis in Mice. Gastroenterology, 2009, 137, 1746-1756.e1.	1.3	77

#	Article	IF	Citations
19	Prognostic significance of mammalian sterile20-like kinase 1 in colorectal cancer. Modern Pathology, 2007, 20, 331-338.	5.5	69
20	Node-Negative Colorectal Cancer at High Risk of Distant Metastasis Identified by Combined Analysis of Lymph Node Status, Vascular Invasion, and Raf-1 Kinase Inhibitor Protein Expression. Clinical Cancer Research, 2008, 14, 143-148.	7.0	69
21	CEACAM1 dampens antitumor immunity by down-regulating NKG2D ligand expression on tumor cells. Journal of Experimental Medicine, 2011, 208, 2633-2640.	8.5	64
22	IgE/FcεRI-Mediated Antigen Cross-Presentation by Dendritic Cells Enhances Anti-Tumor Immune Responses. Cell Reports, 2015, 10, 1487-1495.	6.4	61
23	Anti-tumor immunity in mismatch repair-deficient colorectal cancers requires type I IFN–driven CCL5 and CXCL10. Journal of Experimental Medicine, 2021, 218, .	8.5	61
24	Loss of APAF-1 expression is associated with tumour progression and adverse prognosis in colorectal cancer. European Journal of Cancer, 2007, 43, 1101-1107.	2.8	60
25	Multimarker phenotype predicts adverse survival in patients with lymph nodeâ€negative colorectal cancer. Cancer, 2008, 112, 495-502.	4.1	58
26	Differential significance of tumour infiltrating lymphocytes in sporadic mismatch repair deficient versus proficient colorectal cancers: A potential role for dysregulation of the transforming growth factor-1² pathway. European Journal of Cancer, 2007, 43, 624-631.	2.8	57
27	TIA-1 Cytotoxic Granule-Associated RNA Binding Protein Improves the Prognostic Performance of CD8 in Mismatch Repair-Proficient Colorectal Cancer. PLoS ONE, 2010, 5, e14282.	2.5	52
28	Overexpression of the receptor for hyaluronic acid mediated motility is an independent adverse prognostic factor in colorectal cancer. Modern Pathology, 2006, 19, 1302-1309.	5.5	51
29	Regulation of Immune Responses by the Neonatal Fc Receptor and Its Therapeutic Implications. Frontiers in Immunology, 2014, 5, 664.	4.8	47
30	Expression of FcRn receptor in placental tissue and its relationship with IgG levels in term and preterm newborns. American Journal of Reproductive Immunology, 2018, 80, e12972.	1.2	47
31	RHAMM, p21 Combined Phenotype Identifies Microsatellite Instability-High Colorectal Cancers with a Highly Adverse Prognosis. Clinical Cancer Research, 2008, 14, 3798-3806.	7.0	46
32	Tumor border configuration added to TNM staging better stratifies stage II colorectal cancer patients into prognostic subgroups. Cancer, 2009, 115, 4021-4029.	4.1	46
33	<scp>CEACAM</scp> 1 on activated <scp>NK</scp> cells inhibits <scp>NKG</scp> 2 <scp>D</scp> â€mediated cytolytic function and signaling. European Journal of Immunology, 2013, 43, 2473-2483.	2.9	44
34	Role of the mitogen-activated protein kinase and phosphoinositide 3-kinase/AKT pathways downstream molecules, phosphorylated extracellular signal–regulated kinase, and phosphorylated AKT in colorectal cancer—A tissue microarray–based approachâ~†. Human Pathology, 2006, 37, 1022-1031.	2.0	40
35	The Short Isoform of the CEACAM1 Receptor in Intestinal T Cells Regulates Mucosal Immunity and Homeostasis via Tfh Cell Induction. Immunity, 2012, 37, 930-946.	14.3	40
36	Two-marker protein profile predicts poor prognosis in patients with early rectal cancer. British Journal of Cancer, 2008, 99, 1712-1717.	6.4	37

#	Article	IF	CITATIONS
37	Characterization of the immunological microenvironment of tumour buds and its impact on prognosis in mismatch repair-proficient and -deficient colorectal cancers. Histopathology, 2011, 59, 482-495.	2.9	37
38	Prognostic impact of \hat{l}^2 -2-microglobulin expression in colorectal cancers stratified by mismatch repair status. Journal of Clinical Pathology, 2012, 65, 996-1002.	2.0	36
39	A simple, cost-effective method for generating murine colonic 3D enteroids and 2D monolayers for studies of primary epithelial cell function. American Journal of Physiology - Renal Physiology, 2017, 313, G467-G475.	3.4	34
40	A homozygousPMS2founder mutation with an attenuated constitutional mismatch repair deficiency phenotype. Journal of Medical Genetics, 2015, 52, 348-352.	3.2	30
41	Cross-presentation of IgG-containing immune complexes. Cellular and Molecular Life Sciences, 2013, 70, 1319-1334.	5.4	28
42	Organoids Provide an Important Window on Inflammation in Cancer. Cancers, 2018, 10, 151.	3.7	27
43	Urokinase-type plasminogen activator is a marker of aggressive phenotype and an independent prognostic factor in mismatch repair-proficient colorectal cancer. Human Pathology, 2010, 41, 70-78.	2.0	24
44	FcRn is a CD32a coreceptor that determines susceptibility to IgG immune complex–driven autoimmunity. Journal of Experimental Medicine, 2020, 217, .	8.5	24
45	Linear Lichen Planopilaris of the Trunk: First Report of a Case. Journal of Cutaneous Medicine and Surgery, 2006, 10, 136-138.	1.2	18
46	Tumor Buds Show Reduced Expression of Laminin-5 Gamma 2 Chain in DNA Mismatch Repair Deficient Colorectal Cancer. Diseases of the Colon and Rectum, 2006, 49, 1193-1202.	1.3	17
47	Comparing docosahexaenoic acid (DHA) concomitant with neoadjuvant chemotherapy versus neoadjuvant chemotherapy alone in the treatment of breast cancer (DHA WIN): protocol of a double-blind, phase II, randomised controlled trial. BMJ Open, 2019, 9, e030502.	1.9	15
48	Transforming growth factor-beta pathway disruption and infiltration of colorectal cancers by intraepithelial lymphocytes. Histopathology, 2006, 49, 371-380.	2.9	14
49	Therapeutic implications of Src independent calcium mobilization in diffuse large B-cell lymphoma. Leukemia Research, 2010, 34, 585-593.	0.8	13
50	Immunoglobulin Transport and Immunoglobulin Receptors. , 2015, , 349-407.		12
51	Vavâ€1 expression correlates with NFκB activation and CD40â€mediated cell death in diffuse large Bâ€cell lymphoma cell lines. Hematological Oncology, 2010, 28, 142-150.	1.7	11
52	MSI-H colorectal cancers preferentially retain and expand intraepithelial lymphocytes rather than peripherally derived CD8+ T cells. Cancer Immunology, Immunotherapy, 2009, 58, 135-144.	4.2	10
53	Beyond IgA: the mucosal immunoglobulin alphabet. Mucosal Immunology, 2010, 3, 324-325.	6.0	10
54	Hyperplastic polyposis and cancer of the colon with gastrinoma of the duodenum. Nature Clinical Practice Oncology, 2006, 3, 281-284.	4.3	9

#	Article	IF	CITATIONS
55	Granuloma annulare associated with hypercalcemia secondary to hyperparathyroidism. International Journal of Dermatology, 2006, 45, 1118-1120.	1.0	6
56	Colorectal cancer cells express functional cell surfaceâ€bound TGFβ. International Journal of Cancer, 2008, 122, 1695-1700.	5.1	6
57	Isolation of endogenous cytosolic DNA from cultured cells. STAR Protocols, 2022, 3, 101165.	1.2	3
58	Neonatal Fc receptors for IgG drive CD8+T cell-mediated anti-cancer immunosurveillance at tolerogenic mucosal sites. Oncolmmunology, 2014, 3, e27844.	4.6	2
59	Biology of Gut Immunoglobulins. , 2012, , 1089-1118.		1
60	Regulation of Immunological Responses by the Neonatal Fc Receptor for IgG, FcRn., 2013, , 189-219.		0
61	Neonatal FC Receptor Cooperates with Classical FC Gamma Receptors to Control Inflammatory Bowel Disease through Regulating Immune Complex Processing. Gastroenterology, 2017, 152, S614.	1.3	0